Animal models of human amyloidoses
US5958883A · kind A · utility
Assignee
Inventor
Key dates
| Filing date | Jun 5, 1995 |
| Grant date | Sep 28, 1999 |
| Priority date | — |
| Expiry date | Jun 5, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA01K2267/0312
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
In vivo assays for selecting candidate therapeutics for inhibiting amyloidoses, such as congophilic and fibrillar .beta./A4 amyloid deposition in brain. A candidate reagent is administered to a first rat in a first infusate comprising .beta./A4 peptide and perlecan by continuous infusion into the hippocampus for at least one week. The candidate reagent is selected as a candidate therapeutic for inhibiting congophilic and fibrillar .beta./A4 amyloid deposition in brain if the first infusate diminishes congo red and thioflavin S staining indicative of amyloid deposition adjacent to the infusion site, as compared with a second rat receiving a second infusate consisting essentially of .beta./A4 peptide and perlecan.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.